DOCSLIB.ORG

Vol. 79 Thursday, No. 39 February 27, 2014 Pages 10951–11294

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vol. 79 Thursday, No. 39 February 27, 2014 Pages 10951–11294 Vol. 79 Thursday, No. 39 February 27, 2014 Pages 10951–11294 OFFICE OF THE FEDERAL REGISTER VerDate Mar 15 2010 21:02 Feb 26, 2014 Jkt 232001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\27FEWS.LOC 27FEWS mstockstill on DSK4VPTVN1PROD with FEDREGWS II Federal Register / Vol. 79, No. 39 / Thursday, February 27, 2014 The FEDERAL REGISTER (ISSN 0097–6326) is published daily, SUBSCRIPTIONS AND COPIES Monday through Friday, except official holidays, by the Office PUBLIC of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Subscriptions: Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Paper or fiche 202–512–1800 Committee of the Federal Register (1 CFR Ch. I). The Assistance with public subscriptions 202–512–1806 Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official General online information 202–512–1530; 1–888–293–6498 edition. Periodicals postage is paid at Washington, DC. Single copies/back copies: The FEDERAL REGISTER provides a uniform system for making Paper or fiche 202–512–1800 available to the public regulations and legal notices issued by Assistance with public single copies 1–866–512–1800 Federal agencies. These include Presidential proclamations and (Toll-Free) Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public interest. Paper or fiche 202–741–6005 Documents are on file for public inspection in the Office of the Assistance with Federal agency subscriptions 202–741–6005 Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see www.ofr.gov. The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the Federal Register shall be judicially noticed. The Federal Register is published in paper and on 24x microfiche. It is also available online at no charge at www.fdsys.gov, a service of the U.S. Government Printing Office. The online edition of the Federal Register is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6:00 a.m. each day the Federal Register is published and includes both text and graphics from Volume 59, 1 (January 2, 1994) forward. For more information, contact the GPO Customer Contact Center, U.S. Government Printing Office. Phone 202-512-1800 or 866-512-1800 (toll free). E-mail, gpocusthelp.com. The annual subscription price for the Federal Register paper edition is $749 plus postage, or $808, plus postage, for a combined Federal Register, Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the Federal Register including the Federal Register Index and LSA is $165, plus postage. Six month subscriptions are available for one-half the annual rate. The prevailing postal rates will be applied to orders according to the delivery method requested. The price of a single copy of the daily Federal Register, including postage, is based on the number of pages: $11 for an issue containing less than 200 pages; $22 for an issue containing 200 to 400 pages; and $33 for an issue containing more than 400 pages. Single issues of the microfiche edition may be purchased for $3 per copy, including postage. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: U.S. Government Printing Office—New Orders, P.O. Box 979050, St. Louis, MO 63197-9000; or call toll free 1- 866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, see bookstore.gpo.gov. There are no restrictions on the republication of material appearing in the Federal Register. How To Cite This Publication: Use the volume number and the page number. Example: 77 FR 12345. Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Printing Office, Washington, DC 20402, along with the entire mailing label from the last issue received. VerDate Mar 15 2010 21:02 Feb 26, 2014 Jkt 232001 PO 00000 Frm 00002 Fmt 4710 Sfmt 4710 E:\FR\FM\27FEWS.LOC 27FEWS mstockstill on DSK4VPTVN1PROD with FEDREGWS III Contents Federal Register Vol. 79, No. 39 Thursday, February 27, 2014 Agency for International Development PROPOSED RULES NOTICES Energy Conservation Program for Certain Commercial and Meetings: Industrial Equipment: Advisory Committee on Voluntary Foreign Aid, 11074 Test Procedure for Commercial Water Heating Equipment, 10999–11004 Agriculture Department See Animal and Plant Health Inspection Service Environmental Protection Agency See Forest Service RULES Animal and Plant Health Inspection Service Air Quality State Implementation Plans; Approvals and PROPOSED RULES Promulgations: Importation of Beef From a Region in Brazil, 10999 Wisconsin; Transportation Conformity Procedures, 10995–10998 Army Department Revisions to Test Methods and Testing Regulations, 11228– NOTICES 11294 Meetings: PROPOSED RULES Army Education Advisory Committee, 11093 Air Quality State Implementation Plans; Approvals and Promulgations: Centers for Medicare & Medicaid Services Wisconsin; Transportation Conformity Procedures, 11050 NOTICES NOTICES Hearings: Agency Information Collection Activities; Proposals, Compliance of Florida State Plan Provisions Concerning Submissions, and Approvals: Payment for Outpatient Hospital Services, etc., Regulation of Fuels and Fuel Additives, etc.; Petition for 11110–11112 International Aggregate Compliance Approach, 11101–11102 Commerce Department Draft Guidelines: See International Trade Administration Product Environmental Performance Standards and PROPOSED RULES Ecolabels for Voluntary Use in Federal Procurement, Public Information, Freedom of Information Act and 11102 Privacy Act Regulations, 11025–11037 Pesticide Products: Registration Applications to Register New Uses, 11102– Consumer Product Safety Commission 11104 NOTICES Settlements: Meetings: Yosemite Slough Superfund Site, San Francisco, CA; Potential Ways to Reduce Third Party Testing Costs CERCLA, 11104 through Determinations Consistent with Assuring Compliance, 11088–11091 Executive Office of the President Defense Department See Trade Representative, Office of United States See Army Department PROPOSED RULES Privacy Act; Implementation, 11048–11050 Export-Import Bank NOTICES NOTICES Privacy Act; System of Records, 11091–11093 Agency Information Collection Activities; Proposals, Submissions, and Approvals, 11104 Drug Enforcement Administration RULES Schedules of Controlled Substances: Federal Aviation Administration Placement of Alfaxalone into Schedule IV, 10985–10989 RULES PROPOSED RULES Airworthiness Directives: Schedules of Controlled Substances: Saab AB, Saab Aerosystems Airplanes, 10959–10962 Rescheduling of Hydrocodone Combination Products PROPOSED RULES from Schedule III to Schedule II, 11037–11045 Airworthiness Directives: Airbus Airplanes, 11016–11022 Education Department Bombardier, Inc. Airplanes, 11022–11025 NOTICES Embraer S.A. Airplanes, 11013–11016 Agency Information Collection Activities; Proposals, Changes to Production Certificates and Approvals, 11004– Submissions, and Approvals: 11013 Federal Direct Consolidation Loan Program Application NOTICES Documents, 11093–11094 Consensus Standards, Light-Sport Aircraft, 11175–11177 Meetings: Energy Department Government/Industry Aeronautical Charting Forum, See Federal Energy Regulatory Commission 11177 VerDate Mar<15>2010 21:12 Feb 26, 2014 Jkt 232001 PO 00000 Frm 00001 Fmt 4748 Sfmt 4748 E:\FR\FM\27FECN.SGM 27FECN TKELLEY on DSK3SPTVN1PROD with CONTENTS IV Federal Register / Vol. 79, No. 39 / Thursday, February 27, 2014 / Contents Federal Communications Commission NOTICES PROPOSED RULES Agency Information Collection Activities; Proposals, Petition for Reconsideration of Action in Rulemaking Submissions, and Approvals: Proceeding, 11052–11053 Evaluation of the General Market Youth Tobacco NOTICES Prevention Campaign, 11112 Agency Information Collection Activities; Proposals, Prescription Drug Advertisements, 11112–11114 Submissions, and Approvals, 11105–11107 Foreign Assets Control Office Federal Energy Regulatory Commission NOTICES NOTICES Iran General Licenses E and F, 11180–11181 Applications: Antrim Treatment Trust, 11094–11095 Forest Service Combined Filings, 11096 NOTICES Exempt Wholesale Generator or Foreign Utility Company Land Management Plans: Status: Carson National Forest; Ecological/Social/Economic Lakeland Solar Energy LLC, et al., 11096–11097 Sustainability, Conditions, and Trends Assessment Filings: Report, 11074–11075 Southern Cross Transmission, LLC, and Pattern Power Meetings: Marketing, LLC, 11097 Prince of Wales Island Resource Advisory Committee, Meetings: 11075 Third-Party Provision of Reactive Supply and Voltage Control and Regulation and Frequency Response Health and Human Services Department Services, 11097–11100 See Centers for Medicare & Medicaid Services Refund Effective Dates: See Food and Drug Administration Midcontinent Independent
Load more

Recommended publications
  • Europæisk Patentskrift
    (19) DANMARK (1°) DK/EP 2968225 T3 (12) Oversættelse af europæisk patentskrift Patent- og Varemærkestyrelsen (51) lnt.CI.: A 61 K 31/137 (2006.01) A 61 K 9/00 (2006.01) A 61 K 31/245 (2006.01) A 61 K 31/445 (2006.01) A 61 K 31/519 (2006.01) A 61 K 31/52 (2006.01) A 61 P 43/00 (2006.01) (45) Oversættelsen bekendtgjort den: 2019-05-27 (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: 2019-02-20 (86) Europæisk ansøgning nr.: 14719486.4 (86) Europæisk indleveringsdag: 2014-03-17 (87) Den europæiske ansøgnings publiceringsdag: 2016-01-20 (86) International ansøgning nr.: US2014030372 (87) Internationalt publikationsnr.: WO2014145580 (30) Prioritet: 2013-03-15 US 201361789054 P (84) Designerede stater: AL AT BE BG CH CY CZ DE DK EE ES Fl FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (73) Patenthaver: The Children's Medical Center Corporation, 55 Shattuck Street, Boston, Massachusetts 02115, USA (72) Opfinder: BERDE, Charles, 14 Doran Road, Bookline, MA 02146, USA KOHANE, Daniel S., 119 Willard Street, Newton, MA 02461, USA (74) Fuldmægtig i Danmark: AWA Denmark A/S, Strandgade 56,1401 København K, Danmark (54) Benævnelse: NEOSAXITOXINKOMBINATIONSFORMULERINGER TIL FORLÆNGET LOKALANÆSTESI (56) Fremdragne publikationer: WO-A2-98/51290 ALBERTO J. RODRIGUEZ-NAVARRO ET AL: "Potentiation of Local Anesthetic Activity of Neosaxitoxin with Bupivacaine or Epinephrine: Development of a Long-Acting Pain Blocker", NEUROTOXICITY RESEARCH, vol. 16, no. 4, 28 July 2009 (2009-07-28), pages 408-415, XP055122925, ISSN: 1029-8428, DOI: 10.1007/s12640-009- 9092-3 cited in the application Anonymous: "NCT01786655 on 2013_02_11: ClinicalTrials.gov Archive",, 11 February 2013 (2013-02-11), XP055122935, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCTO 1786655/2013_02_11 [retrieved on 2014-06-12] CHARLES B.
    [Show full text]
  • Local Anesthetics – Substances with Multiple Application in Medicine
    ISSN 2411-958X (Print) European Journal of January-April 2016 ISSN 2411-4138 (Online) Interdisciplinary Studies Volume 2, Issue 1 Local Anesthetics – Substances with Multiple Application in Medicine Rodica SÎRBU Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Emin CADAR UMF Carol Davila Bucharest, Faculty of Pharmacy, Str. Traian Vuia No. 6, Sector 2, Bucharest, Romania Cezar Laurențiu TOMESCU Ovidius University of Constanta, Faculty of Medicine, Campus Corp B, University Alley No. 1, Constanta, Romania Cristina-Luiza ERIMIA Corresponding author, [email protected] Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Stelian PARIS Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Aneta TOMESCU Ovidius University of Constanta, Faculty of Medicine, Campus Corp B, University Alley No. 1, Constanta, Romania Abstract Local anesthetics are substances which, by local action groups on the runners, cause loss of reversible a painful sensation, delimited corresponding to the application. They allow small surgery, short in duration and the endoscopic maneuvers. May be useful in soothe teething pain of short duration and in the locking of the nervous disorders in medical care. Local anesthesia is a process useful for the carrying out of surgery and of endoscopic maneuvers, to soothe teething pain in certain conditions, for depriving the temporary structures peripheral nervous control. Reversible locking of the transmission nociceptive, the set of the vegetative and with a local anesthetic at the level of the innervations peripheral nerve, roots and runners, a trunk nervous, around the components of a ganglion or coolant is cefalorahidian practice anesthesia loco-regional.
    [Show full text]
  • Advances in Interference Removal for Accurate Arsenic Analysis in Food
    Advances in National Environmental Interference Removal Monitoring Conference 2013 for Accurate Arsenic Austin TX Analysis in Food and Steve Wilbur and Amir Liba Beverages Agilent Technologies Let’s Define the Problem -Medically, legally, analytically Arsenic is toxic (but not all forms are toxic to the same degree) Arsenic is present in drinking waters and many foods (but the form varies) Toxicity depends on the form or species (but species conservation during sample prep is challenging) Arsenic is challenging to determine by ICP-MS because it is monoisotopic, has a high ionization potential, and is subject to many common spectroscopic interferences. Inorganic arsenic-related health effects Inorganic arsenic is a well-characterized Group 1 human carcinogen • Lung, bladder, skin and others • Transplacental carcinogen Noncancer health effects • Cardiovascular disease • Diabetes mellitus • Dermal effects • Neurological effects/deficits • Immunologic effects • Fertility effects • Birth defects • Respiratory effects Acute toxicity • Irritation of lungs, throat, stomach, intestines and skin • Death within hours after ingestion of sufficient dose Arsenic in water – inorganic arsenic As(III) and As(V) British Geological Survey As species* *Analyst. 2004, 129, 373-395 More arsenic species* *Analyst. 2004, 129, 373-395 As Speciation - Toxicity Toxic! Many As species exist – the inorganic As species are known Less-Toxic to be toxic and most organic species are Non-Toxic relatively harmless to humans. The potential toxicity of some species, such
    [Show full text]
  • Alfa Laval Black and Grey List, Rev 14.Pdf 2021-02-17 1678 Kb
    Alfa Laval Group Black and Grey List M-0710-075E (Revision 14) Black and Grey list – Chemical substances which are subject to restrictions First edition date. 2007-10-29 Revision date 2021-02-10 1. Introduction The Alfa Laval Black and Grey List is divided into three different categories: Banned, Restricted and Substances of Concern. It provides information about restrictions on the use of Chemical substances in Alfa Laval Group’s production processes, materials and parts of our products as well as packaging. Unless stated otherwise, the restrictions on a substance in this list affect the use of the substance in pure form, mixtures and purchased articles. - Banned substances are substances which are prohibited1. - Restricted substances are prohibited in certain applications relevant to the Alfa Laval group. A restricted substance may be used if the application is unmistakably outside the scope of the legislation in question. - Substances of Concern are substances of which the use shall be monitored. This includes substances currently being evaluated for regulations applicable to the Banned or Restricted categories, or substances with legal demands for monitoring. Product owners shall be aware of the risks associated with the continued use of a Substance of Concern. 2. Legislation in the Black and Grey List Alfa Laval Group’s Black and Grey list is based on EU legislations and global agreements. The black and grey list does not correspond to national laws. For more information about chemical regulation please visit: • REACH Candidate list, Substances of Very High Concern (SVHC) • REACH Authorisation list, SVHCs subject to authorization • Protocol on persistent organic pollutants (POPs) o Aarhus protocol o Stockholm convention • Euratom • IMO adopted 2015 GUIDELINES FOR THE DEVELOPMENT OF THE INVENTORY OF HAZARDOUS MATERIALS” (MEPC 269 (68)) • The Hong Kong Convention • Conflict minerals: Dodd-Frank Act 1 Prohibited to use, or put on the market, regardless of application.
    [Show full text]
  • P-Aminobenzoic Acid Derivatives Benzocaine
    P-aminobenzoic acid derivatives Benzocaine Mechanism of action oThe loca l anaesthe tics decrease the excitabilit y of nerve cells by decreasing the entry of Na+ ions during upstroke of action pottiltential. oThe local anaesthetics interact with a receptor situated within the voltage sensitiesensitive Na+ channel and raise the threshold of channel opening. oLocal anaesthetic blocks Na+ conductance by two possible modes of action, the tonic and the phasic inhibition. oTonic inhibition results from the binding of LA to nonactivated closed channel while phasic inhibition results from the binding of LA to open state or inactivate state of channels. Uses: For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea and urinary tract. Procaine MOA: Similar to benzocaine Uses: For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea and urinary tract. Butamben IUPAC: Butyl 4-aminobenzoate MOA: Similar to benzocaine Uses: For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea and urinary tract. Butacaine IUPAC: 3-(dibutylamino)propyl 4´-aminobenzoate MOA: Similar to benzocaine Uses: For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea and urinary tract. Benox inate IUPAC: 2-(diethylamino)ethyl 4´-amino-3´-butoxybenzoate MOA: Similar to benzocaine Uses: For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea and urinary tract. Tetracaine IUPAC: 2-(dimethylamino)ethyl 4´-(butylamino)benzoate MOA: Similar to benzocaine Uses: For general use as a lubricant and topical anesthetic on esoppghagus, laryyypynx, mouth, nasal cavity, rectum, respiratory tract or trachea and urinary tract..
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Cocaine in Seized Materials
    Recommended methods for the Identification and Analysis of Cocaine in Seized Materials MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits: UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Cocaine in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS New York, 2012 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases, but any modification has to be validated before it is integrated into laboratory routines. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. ST/NAR/7/REV.1 Original language: English © United Nations, March 2012. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. ii Contents Page 1. Introduction ................................................. 1 1.1 Background .............................................. 1 1.2 Purpose and use of the manual .............................. 1 2. Physical appearance and chemical characteristics of coca leaf and illicit materials containing cocaine ................................
    [Show full text]
  • WO 2008/034819 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 27 March 2008 (27.03.2008) WO 2008/034819 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K9/00 (2006.01) A61K 31/16 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/18 (2006.01) AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, (21) International Application Number: ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, PCT/EP2007/059827 IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, (22) International Filing Date: MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, 18 September 2007 (18.09.2007) PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 06121 134.8 22 September 2006 (22.09.2006) EP ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): PHAR- European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, MATEX ITALIA SRL [IT/IT]; Via Andrea Appiani, 2, FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, 1-20121 Milano (IT).
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • US5276032.Pdf
    ||||||||||I|| USOO5276.032A United States Patent (19) 11 Patent Number: 5,276,032 King et al. 45) Date of Patent: Jan. 4, 1994 54 VISION AD AND ANESTHETC 56) References Cited COMPOSTON U.S. PATENT DOCUMENTS 1,907,392 5/1933 Stover ... ... 514/535 76) Inventors: O. Newton King, 2524 Yale Rd.; 2,382,546 8/1945 Curtis .... ... 54/535 X Henry W. Buck, 306 Homestead Dr., 2,803,582 8/1957 Cherney...... ... S4/535 X both of, Lawrence, Kans, 66049 3,019,163 1/1962 Harnist et al. ... 54/535 X 4,748,022 5/1988 Busciglio .......................... 424/95. FOREIGN PATENT DOCUMENTS 21 Appl. No.: 788,932 460629 1/1937 United Kingdom . Primary Examiner-Frederick E. Waddell 22) Fied: Nov. 7, 1991 Assistant Examiner-T. J. Criares 57 ABSTRACT Related U.S. Application Data A new visualizing and anesthetic composition and the process for the preparation thereof. The composition, 63 Continuation of Ser. No. 458,300, Dec. 28, 1989, aban generally as a gel, contains an effective amount of a doned. topical anesthetic, an effective amount of a visualizing agent and a pharmaceutically acceptable gelling reser 51 Int. Cl. ................. A61K 31/535; A61K 31/445; voir as a heat exchanger and/or a light transmitter. The A61K 31/24; A61K 47/00 composition is useful for topical application to a region (52) U.S. C. ................................. 514/239.2; 514/317; of mammalian skin to supply visualization to a lesion 514/535; 514/626, 514/536; 514/781; 514/944; therein and to anesthetize the region for a subsequent 514/967; 514/969 destructive therapy.
    [Show full text]
  • Butacaine Sulfate/Coca 1857
    Butacaine Sulfate/Coca 1857 Butyl Aminobenzoate block) because of a high incidence of thrombophlebitis associat- Cinchocaine Hydrochloride (BANM, rINNM) ed with such use. It is also contra-indicated in spinal anaesthesia Butamben (USAN); Butilaminobenzoato; Butoforme. Butyl 4-ami- due to potential neurotoxicity. Cincaini Chloridum; Cinchocaïne, chlorhydrate de; Cinchocaini nobenzoate. hydrochloridum; Cinchokain-hidroklorid; Cinchokain-hydrochlo- C11H15NO2 = 193.2. Interactions rid; Cinchokaino hidrochloridas; Cinkokainhydroklorid; Dibu- CAS — 94-25-7. For interactions associated with local anaesthetics, see p.1851. caine Hydrochloride; Dibucainium Chloride; Hidrocloruro de Pharmacokinetics cincocaína; Percainum; Sinkokaiinihydrokloridi; Sinkokain Hid- Chloroprocaine is hydrolysed rapidly in the circulation by plas- roklorür; Sovcainum. O O CH 3 ma cholinesterase. It has a half-life of 19 to 26 seconds in adults. Цинхокаина Гидрохлорид It is excreted in the urine mainly as metabolites. C H N O ,HCl = 379.9. See also under Local Anaesthetics, p.1852. 20 29 3 2 CAS — 61-12-1. Uses and Administration ATC — C05AD04; D04AB02; N01BB06; S01HA06. Chloroprocaine, a para-aminobenzoic acid ester, is a local anaes- ATC Vet — QC05AD04; QD04AB02; QN01BB06; thetic with actions and uses similar to those described on p.1852. QS01HA06. It has properties similar to those of procaine (p.1869). It has a NH2 rapid onset (6 to 12 minutes) and short duration (one hour) of NOTE. This compound was originally marketed under the name action. Percaine, but accidents occurred owing to the confusion of this Pharmacopoeias. In Fr. and US. name with procaine. Chloroprocaine is used as the hydrochloride for infiltration, pe- USP 31 (Butamben). A white, odourless, crystalline powder. ripheral nerve block, and central nerve block including lumbar Pharmacopoeias.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]